Darmiyan
YC S17San Francisco, US · 8 employees · 2 known investors
Darmiyan develops medical AI and brain imaging software for early detection and monitoring of neurodegenerative diseases, particularly Alzheimer's. The platform targets healthcare providers, patients, and pharmaceutical companies seeking to advance brain health and disease prevention.
AI & Machine LearningDigital HealthHealthtechMedical DevicesArtificial IntelligenceMachine LearningHealth TechDiagnosticsin /company@ycombinator
Founders & leadership· Y Combinator alumni (S17)
Padideh Kamali-ZareinFounder
Kaveh VejdaniinFounder/Chief Medical and Technology Officer
Investors · 2
In the news
- Nudge - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2025
- AI Weekly: 01/16/24 - by Zach Gronfein - AI Weeklysoundai.substack.com · 2024
- FDA clears AI that predicts Alzheimer’s progression from an MRI scanfiercebiotech.com · 2024
- Global Pharma Giant Eisai Leads a $6M Series Seed Investment Round in Darmiyan to Expedite its Clinical Market Entryprnewswire.com · 2020
- Darmiyan Raises $6M in Initial Close of Seed Funding - FinSMEsfinsmes.com · 2020